RxDoctor Payments DataLook up a doctor →

Janell Powell, MD

Internal Medicine · Sioux Falls, SDNPI 1750309357

Payments from drug & device makers

$6,862in general payments, 2019–2025

Across 421 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$907
  • Astellas Pharma US Inc$649
  • Novo Nordisk$497
  • Amgen$464
  • Boehringer Ingelheim$373
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,54895%
  • Education$3145%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,862 in reported general payments places this provider in the 95th percentile of 178 internal medicine providers in South Dakota.

See all internal medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$95,586
Medicare patients
458
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$95,632
MounjaroTirzepatide76$82,833
TrulicityDulaglutide70$73,209
JardianceEmpagliflozin53$66,693
OzempicSemaglutide31$36,781
JanuviaSitagliptin Phosphate32$25,244
Breo ElliptaFluticasone/Vilanterol34$19,318
XareltoRivaroxaban11$13,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,064
SynthroidLevothyroxine Sodium80$7,165
Levothyroxine Sodium805$6,651
Potassium Chloride233$5,598
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,621
Omeprazole471$4,606
Atorvastatin Calcium597$4,479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$907$156,042146 claims
PfizerEliquis, Paxlovid$320$97,061133 claims
Boehringer IngelheimJardiance$373$66,69353 claims
Novo NordiskOzempic$497$36,78131 claims
GSKBreo Ellipta, Trelegy Ellipta$174$31,38353 claims
MerckJanuvia$129$25,24432 claims
Johnson & JohnsonXarelto$90$13,70311 claims
AbbVieSynthroid$1,065$7,16580 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$188$4,42012 claims
Sanofi-aventis U.S. LLCLantus$36$1,34318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 178 internal medicine providers in South Dakota.

Other internal medicine in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →